Experienced in Chronic B-Cell Leukemia (CBCL)

Soo Aleman

Karolinska Institutet
Huddinge, AB, SE 
Experienced in Chronic B-Cell Leukemia (CBCL)
Karolinska Institutet
Huddinge, AB, SE 
OverviewLocationsClinical Research

Overview

Soo Aleman practices in Huddinge, Sweden. Ms. Aleman is rated as an Experienced expert by MediFind in the treatment of Chronic B-Cell Leukemia (CBCL). Her top areas of expertise are Hepatitis D, Hepatitis, Hepatitis C, and Severe Acute Respiratory Syndrome (SARS).

Her clinical research consists of co-authoring 125 peer reviewed articles and participating in 1 clinical trial. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 6 articles in the study of Chronic B-Cell Leukemia (CBCL).

Gender
Female

Locations

Karolinska Institutet
Huddinge, AB, Sweden
Other Locations
Stockholm, AB 14157, Sweden
Solna, AB, Sweden

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

A Phase 3, Matrix Design, Partially Double-Blind, Randomized Study of the Efficacy and Safety of 50 mg Lonafarnib/100 mg Ritonavir BID With and Without 180 mcg PEG IFN-alfa-2a for 48 Weeks Compared With PEG IFN-alfa-2a Monotherapy and Placebo Treatment in Patients Chronically Infected With Hepatitis Delta Virus Being Maintained on Anti-HBV Nucleos(t)Ide Therapy (D-LIVR)
A Phase 3, Matrix Design, Partially Double-Blind, Randomized Study of the Efficacy and Safety of 50 mg Lonafarnib/100 mg Ritonavir BID With and Without 180 mcg PEG IFN-alfa-2a for 48 Weeks Compared With PEG IFN-alfa-2a Monotherapy and Placebo Treatment in Patients Chronically Infected With Hepatitis Delta Virus Being Maintained on Anti-HBV Nucleos(t)Ide Therapy (D-LIVR)
Enrollment Status: Completed
Publish Date: April 14, 2023
Intervention Type: Drug
Study Drugs: Lonafarnib, Ritonavir, PEG IFN-alfa-2a
Study Phase: Phase 3

125 Total Publications

Corrigendum to "Sociodemographic factors influencing SARS-CoV-2 vaccination uptake in people with and without HIV: Insights from a Swedish Nationwide cohort" [Vaccine 62 (2025) 127580].
Corrigendum to "Sociodemographic factors influencing SARS-CoV-2 vaccination uptake in people with and without HIV: Insights from a Swedish Nationwide cohort" [Vaccine 62 (2025) 127580].
Journal: Vaccine
Published: October 18, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Aleman's expertise for a condition
ConditionClose
View All 12 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile